Developer docs
API playgroundTry for free, no card

Search company profiles

Senzime

Full company profile

uuid0003iq6

Namestring
Senzime
Legal namestring
Senzime AB (publ)
Websiteurl
senzime.com
Company typeenum
Public
Founded yearint
2006
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromuscular monitoring, patient monitoring systems, EMG sensors, respiratory monitoring, anesthesia equipment
Industry3 codes
PRIMARYHLAHADAJ
Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Patient Monitoring Systems - Neuromuscular Monitoring
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1TetraGraph Hardware Systems
TypeHardware Sales
Description

Sale of TetraGraph neuromuscular monitoring devices including monitors and sensors. Monitor sales to hospitals and surgical centers, generating recurring sensor revenue.

senzime.com
2EMG Sensors (Recurring)
TypeUsage Based
Description

Recurring sales of TetraSens and other EMG sensors for use with TetraGraph systems. Sensors are single-use disposable products requiring regular repurchase.

senzime.com
3TetraAnalytics Software Platform
TypeSubscription Recurring
Description

Cloud-based analytics platform for next-generation TetraGraph users, potentially with subscription or per-user pricing.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1No public pricing available
ModelOtherBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed

senzime.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1TetraGraph
Description

Quantitative neuromuscular monitoring system using EMG technology for train-of-four monitoring during surgery

senzime.com
+5 more records
Core offering1 text field

Senzime develops, manufactures, and sells precision-based patient monitoring systems for hospitals and surgical centers, centered on the TetraGraph quantitative Train-of-Four (TOF) neuromuscular monitoring platform that uses electromyography (EMG) to optimize dosing of muscle relaxants and assess patient readiness for extubation. The company also sells single-use EMG sensors, a cloud-based analytics platform (TetraAnalytics), an EHR connectivity platform (TetraCom), the EMGINE software suite, and the ExSpiron non-invasive respiratory volume monitoring system acquired from Respiratory Motion.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 43% reduction in postoperative pulmonary complications when TOFR >0.90 achieved
+5 more records
Product overview1 text field

Senzime offers a portfolio of precision-based patient monitoring solutions centered around the TetraGraph system for neuromuscular blockade monitoring during surgery. The product line includes the core TetraGraph neuromuscular monitoring system (available in next-generation and classic versions), TetraSens EMG sensors, TetraCom EHR connectivity platform, TetraAnalytics cloud-based data analytics platform, and EMGINE Software Suite. The ExSpiron non-invasive respiratory volume monitoring system was acquired through Respiratory Motion. Products are designed for use in operating rooms, ICUs, and hospital settings, with a focus on anesthesia-to-recovery patient safety. Senzime operates direct sales teams in the US and Germany, with licensing partners in Japan and China, and distributors covering over 30 markets.

Product and service6 records
1TetraGraph Neuromuscular Monitoring System
CategoryPatient Monitoring - Neuromuscular
Description

Quantitative Train-of-Four (TOF) neuromuscular monitoring system used by anesthesiologists during surgery to monitor neuromuscular function, optimize dosing of muscle relaxants, and assess patient readiness for extubation. Available in next-generation and classic versions. Used by over 750 hospitals worldwide.

2TetraSens EMG Sensor
CategoryPatient Monitoring - Disposable Sensor
Description

Single-use EMG sensor designed for use with the TetraGraph system, featuring 50% less dielectric material than legacy sensors. Manufactured in Europe with environmentally friendly process and regional supply chain. Generates recurring sensor revenue for the company.

3TetraAnalytics Data Analytics Platform
CategoryHealthcare Analytics Software
Description

Cloud-based data analytics platform for next-generation TetraGraph users that transforms invisible patterns into operational insights, featuring flexible data analysis with customizable dashboards, summaries, comparisons, and reports, the Train-of-Four Quality Indicator (TQi), and centralized remote team collaboration tools.

4ExSpiron Respiratory Volume Monitor
CategoryPatient Monitoring - Respiratory
Description

Non-invasive respiratory volume monitoring system for monitoring respiratory function during and after surgery. Acquired through the Respiratory Motion acquisition in 2022. Addresses respiratory and vital signs monitoring needs outside the operating room.

5TetraCom EHR Connectivity Platform
CategoryHealthcare Connectivity / Integration Platform
Description

Hospital connectivity platform combining compact hardware gateway with cloud-based software using HL7 messaging standards to enable universal wireless transmission of neuromuscular monitoring data directly into hospital enterprise systems such as Epic and Oracle Health, eliminating manual charting and enabling automated documentation.

6EMGINE Software Suite
CategoryMedical Device Software
Description

Software platform for the TetraGraph system including Sirius features with intubation readiness indicator, personalized monitoring, and high-current stimulation capabilities, built on extensive clinical data.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-24
Description

Leading US Group Purchasing Organization. Vizient agreement removes structural barriers in US procurement process and creates foundation for broader hospital network adoption.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-24
Description

Leading US Group Purchasing Organization. Premier agreement enables system-wide contracts with hospital networks through GPO procurement.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-24
Description

Leading US Group Purchasing Organization. HealthTrust agreement covers combined annual purchasing volumes exceeding USD 200 billion with approximately 95% of US hospitals engaging with GPOs.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-17
Description

Partnership for distribution and commercialization of Next-generation TetraGraph system in Japan. Fukuda Denshi received regulatory approval from PMDA and launched HN-100 NMT Monitoring Module integrating Senzime's EMG technology. Fukuda Denshi has been active in Japan since 2019.

5Healthcare 21 Group
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-09
Description

UK partner facilitating Senzime's NHS hospital contracts. Healthcare 21 enabled the 70-unit order from leading NHS hospital trust, the largest European order for Senzime.

pharmiweb.com
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-10-10
Description

Fukuda Denshi launched HN-100 Neuromuscular Transmission Monitoring Module in US market integrating advanced EMG technology from Senzime AB for real-time neuromuscular function monitoring during anesthesia care.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in EMG-based quantitative Train-of-Four neuromuscular monitoring with the TOF-Cuff and TOF-Scan products, targeting the same anesthesia provider customers in US and European hospitals. Closest like-for-like peer for TetraGraph.

TypeDirect peer
Description

Earlier-stage developer of EMG-based neuromuscular monitoring technology competing directly with Senzime's TetraGraph in the perioperative quantitative TOF segment. Closely comparable on technology approach and target use case.

3Drägerwerk
TypeBroad incumbent
Description

Major anesthesia workstation and patient monitoring incumbent whose Infinity and Perseus platforms integrate quantitative neuromuscular monitoring. Competes for the same hospital capital budget and OR footprint but as part of a much broader portfolio.

TypeBroad incumbent
Description

Broad patient monitoring and anesthesia delivery incumbent with CARESCAPE and Aisys platforms that integrate neuromuscular monitoring modules. Competes for hospital OR monitoring budgets across vital signs and anesthesia.

TypeBroad incumbent
Description

Global patient monitoring leader whose IntelliVue and bedside monitoring ecosystems overlap with Senzime's perioperative monitoring use case, especially in integrated hospital enterprise deployments.

TypeBroad incumbent
Description

Patient monitoring and pulse oximetry leader whose SedLine brain monitoring and rainbow sensors compete in the perioperative monitoring space; SET pulse oximetry is a standard of care adjacent to neuromuscular monitoring.

TypeBroad incumbent
Description

Major Chinese patient monitoring and anesthesia equipment manufacturer with broad OR and ICU monitoring portfolios that include neuromuscular modules. Competes on price and on bundled anesthesia solutions globally.

8Nihon Kohden
TypeRegional player
Description

Japanese patient monitoring leader whose OR and bedside monitors overlap with Senzime's perioperative use case; particularly relevant given Senzime's Japan expansion via Fukuda Denshi.

TypeRegional player
Description

Senzime's Japanese licensing partner which launched the HN-100 NMT module integrating Senzime's EMG technology. Comparable as a Japanese anesthesia/monitoring vendor and as a direct commercialization channel for TetraGraph in Japan.

TypeBroad incumbent
Description

Hemodynamic and minimally invasive patient monitoring incumbent with strong hospital critical-care footprint, including advanced parameters in the OR setting; comparable on enterprise hospital monitoring sales motion but differentiated clinically.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Senzime

Patient Monitoring Systems - Neuromuscular Monitoringsenzime.com

Senzime firmographics

Firmographics
Name
Senzime
Legal name
Senzime AB (publ)
Website
https://senzime.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Senzime industry classification

Industry
Product category
Patient Monitoring Systems - Neuromuscular Monitoring
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAJ
Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Neuromuscular monitoring
  • Patient monitoring systems
  • EMG sensors
  • Respiratory monitoring
  • Anesthesia equipment

Where Senzime is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices3 records

Markets served

Senzime business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. TetraGraph Hardware Systems: Sale of TetraGraph neuromuscular monitoring devices including monitors and sensors. Monitor sales to hospitals and surgical centers, generating recurring sensor revenue.
  2. EMG Sensors (Recurring): Recurring sales of TetraSens and other EMG sensors for use with TetraGraph systems. Sensors are single-use disposable products requiring regular repurchase.
  3. TetraAnalytics Software Platform: Cloud-based analytics platform for next-generation TetraGraph users, potentially with subscription or per-user pricing.

Pricing tiers

ModelBillingPrice
OtherAnnualNo public pricing available

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Senzime product offering

Product offering

Core offering

Senzime develops, manufactures, and sells precision-based patient monitoring systems for hospitals and surgical centers, centered on the TetraGraph quantitative Train-of-Four (TOF) neuromuscular monitoring platform that uses electromyography (EMG) to optimize dosing of muscle relaxants and assess patient readiness for extubation. The company also sells single-use EMG sensors, a cloud-based analytics platform (TetraAnalytics), an EHR connectivity platform (TetraCom), the EMGINE software suite, and the ExSpiron non-invasive respiratory volume monitoring system acquired from Respiratory Motion.

Product overview

Senzime offers a portfolio of precision-based patient monitoring solutions centered around the TetraGraph system for neuromuscular blockade monitoring during surgery. The product line includes the core TetraGraph neuromuscular monitoring system (available in next-generation and classic versions), TetraSens EMG sensors, TetraCom EHR connectivity platform, TetraAnalytics cloud-based data analytics platform, and EMGINE Software Suite. The ExSpiron non-invasive respiratory volume monitoring system was acquired through Respiratory Motion. Products are designed for use in operating rooms, ICUs, and hospital settings, with a focus on anesthesia-to-recovery patient safety. Senzime operates direct sales teams in the US and Germany, with licensing partners in Japan and China, and distributors covering over 30 markets.

Differentiator

Problem solved

Functional benefit

Brands

  • TetraGraph: Quantitative neuromuscular monitoring system using EMG technology for train-of-four monitoring during surgery
  • TetraSens
  • EMGINE
  • TetraCom
  • TetraAnalytics
  • ExSpiron

Products and services

  • TetraGraph Neuromuscular Monitoring System Quantitative Train-of-Four (TOF) neuromuscular monitoring system used by anesthesiologists during surgery to monitor neuromuscular function, optimize dosing of muscle relaxants, and assess patient readiness for extubation. Available in next-generation and classic versions. Used by over 750 hospitals worldwide.
  • TetraSens EMG Sensor Single-use EMG sensor designed for use with the TetraGraph system, featuring 50% less dielectric material than legacy sensors. Manufactured in Europe with environmentally friendly process and regional supply chain. Generates recurring sensor revenue for the company.
  • TetraAnalytics Data Analytics Platform Cloud-based data analytics platform for next-generation TetraGraph users that transforms invisible patterns into operational insights, featuring flexible data analysis with customizable dashboards, summaries, comparisons, and reports, the Train-of-Four Quality Indicator (TQi), and centralized remote team collaboration tools.
  • ExSpiron Respiratory Volume Monitor Non-invasive respiratory volume monitoring system for monitoring respiratory function during and after surgery. Acquired through the Respiratory Motion acquisition in 2022. Addresses respiratory and vital signs monitoring needs outside the operating room.
  • TetraCom EHR Connectivity Platform Hospital connectivity platform combining compact hardware gateway with cloud-based software using HL7 messaging standards to enable universal wireless transmission of neuromuscular monitoring data directly into hospital enterprise systems such as Epic and Oracle Health, eliminating manual charting and enabling automated documentation.
  • EMGINE Software Suite Software platform for the TetraGraph system including Sirius features with intubation readiness indicator, personalized monitoring, and high-current stimulation capabilities, built on extensive clinical data.

Quantifiable outcome

  • 43% reduction in postoperative pulmonary complications when TOFR >0.90 achieved
  • +5 more outcomes

Companies that use Senzime

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Senzime technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Senzime partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and strategic.

  • VizientcoreChannel Partner/ Reseller/ Distributor · 24 April 2026Leading US Group Purchasing Organization. Vizient agreement removes structural barriers in US procurement process and creates foundation for broader hospital network adoption.
  • Premier Inc.coreChannel Partner/ Reseller/ Distributor · 24 April 2026Leading US Group Purchasing Organization. Premier agreement enables system-wide contracts with hospital networks through GPO procurement.
  • HealthTrust Performance GroupcoreChannel Partner/ Reseller/ Distributor · 24 April 2026Leading US Group Purchasing Organization. HealthTrust agreement covers combined annual purchasing volumes exceeding USD 200 billion with approximately 95% of US hospitals engaging with GPOs.
  • Fukuda DenshicoreChannel Partner/ Reseller/ Distributor · 17 December 2025Partnership for distribution and commercialization of Next-generation TetraGraph system in Japan. Fukuda Denshi received regulatory approval from PMDA and launched HN-100 NMT Monitoring Module integrating Senzime's EMG technology. Fukuda Denshi has been active in Japan since 2019.
  • Healthcare 21 GroupcoreChannel Partner/ Reseller/ Distributor · 9 December 2025UK partner facilitating Senzime's NHS hospital contracts. Healthcare 21 enabled the 70-unit order from leading NHS hospital trust, the largest European order for Senzime.
  • Fukuda Denshi (US Integration)strategicTechnology or Integration · 10 October 2025Fukuda Denshi launched HN-100 Neuromuscular Transmission Monitoring Module in US market integrating advanced EMG technology from Senzime AB for real-time neuromuscular function monitoring during anesthesia care.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Senzime competitors and assessment

Company assessment

Direct peers

  • Blink Device Company: Direct competitor in EMG-based quantitative Train-of-Four neuromuscular monitoring with the TOF-Cuff and TOF-Scan products, targeting the same anesthesia provider customers in US and European hospitals. Closest like-for-like peer for TetraGraph.
  • Stimdia Medical: Earlier-stage developer of EMG-based neuromuscular monitoring technology competing directly with Senzime's TetraGraph in the perioperative quantitative TOF segment. Closely comparable on technology approach and target use case.

Broad incumbents

  • Drägerwerk: Major anesthesia workstation and patient monitoring incumbent whose Infinity and Perseus platforms integrate quantitative neuromuscular monitoring. Competes for the same hospital capital budget and OR footprint but as part of a much broader portfolio.
  • GE HealthCare: Broad patient monitoring and anesthesia delivery incumbent with CARESCAPE and Aisys platforms that integrate neuromuscular monitoring modules. Competes for hospital OR monitoring budgets across vital signs and anesthesia.
  • Philips (Patient Monitoring): Global patient monitoring leader whose IntelliVue and bedside monitoring ecosystems overlap with Senzime's perioperative monitoring use case, especially in integrated hospital enterprise deployments.
  • Masimo: Patient monitoring and pulse oximetry leader whose SedLine brain monitoring and rainbow sensors compete in the perioperative monitoring space; SET pulse oximetry is a standard of care adjacent to neuromuscular monitoring.
  • Mindray: Major Chinese patient monitoring and anesthesia equipment manufacturer with broad OR and ICU monitoring portfolios that include neuromuscular modules. Competes on price and on bundled anesthesia solutions globally.
  • Edwards Lifesciences: Hemodynamic and minimally invasive patient monitoring incumbent with strong hospital critical-care footprint, including advanced parameters in the OR setting; comparable on enterprise hospital monitoring sales motion but differentiated clinically.

Regional players

  • Nihon Kohden: Japanese patient monitoring leader whose OR and bedside monitors overlap with Senzime's perioperative use case; particularly relevant given Senzime's Japan expansion via Fukuda Denshi.
  • Fukuda Denshi: Senzime's Japanese licensing partner which launched the HN-100 NMT module integrating Senzime's EMG technology. Comparable as a Japanese anesthesia/monitoring vendor and as a direct commercialization channel for TetraGraph in Japan.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Senzime social profiles

Digital presence

Senzime compliance and trust

Trust signal

Compliance3 records

Senzime financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Senzime leadership team

Management profile

Number of profiles

Profiles13 records

Senzime subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Senzime funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Senzime M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Senzime

What does Senzime do?

Senzime develops, manufactures, and sells precision-based patient monitoring systems for hospitals and surgical centers, centered on the TetraGraph quantitative Train-of-Four (TOF) neuromuscular monitoring platform that uses electromyography (EMG) to optimize dosing of muscle relaxants and assess patient readiness for extubation. The company also sells single-use EMG sensors, a cloud-based analytics platform (TetraAnalytics), an EHR connectivity platform (TetraCom), the EMGINE software suite, and the ExSpiron non-invasive respiratory volume monitoring system acquired from Respiratory Motion.

Is Senzime a public or private company?

Senzime is a public company. It is classified as public and is currently operating.

When was Senzime founded?

Senzime was founded in 2006. It employs 51 to 100 people.

Where is Senzime based?

Senzime is headquartered in Uppsala, Sweden, in the Europe region.

How does Senzime make money?

Three revenue lines are on record. TetraGraph Hardware Systems are the primary driver. The others are EMG Sensors (Recurring) and tetraAnalytics Software Platform.

Who are Senzime's main competitors?

Direct peers on record are Blink Device Company and Stimdia Medical. Broad incumbents are Drägerwerk, GE HealthCare, Philips (Patient Monitoring), Masimo, Mindray and Edwards Lifesciences. Regional players are Nihon Kohden and Fukuda Denshi.

Does Senzime have an API?

No public API is recorded for Senzime.

What industry is Senzime in?

Senzime's product category is Patient Monitoring Systems - Neuromuscular Monitoring. Its primary akta.pro industry code is HLAHADAJ, Anesthesia & Airway Management Equipment (Workstations, Laryngoscopy, Ventilation adjuncts), with a secondary code of HLACAFAG, Medical-Grade Device Connectivity & Device Management (MDM). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooSenzime AB (SNZZF) (Q3 2026) Earnings Call Highlights: Record Margins, Philips Partnership and ...Senzime AB reported 14% overall growth in Q3 2026, with sensor sales up 43% and recurring revenue at 83% of the business. Gross margin hit a record 74%, and operating expenses fell 15%, but EBITDA remained negative at -8 million SEK. The company expects positive cash flow in Q4.Seeking AlphaSenzime AB (publ) (SNZZF) Q3 2026 Earnings Call TranscriptSenzime's CEO Philip Siberg presented Q3 2026 results, highlighting the TetraGraph neuromuscular monitoring system. The company has delivered about 6,000 systems to operating rooms, monitored over 1.3 million patients, and derives about 80% of revenue from recurring disposable sensor sales.Seeking AlphaSenzime AB (publ) (SNZZF) Q3 2026 Earnings Call Prepared Remarks TranscriptSenzime reported Q3 growth of 14% across all regions, with disposable sensors growing 43%. The company has delivered about 6,000 TetraGraph systems to over 800 hospitals in 30 markets, monitoring 1.3 million patients. It expects to expand beyond 400,000 operating rooms.Stock TitanSenzime Q3 earnings: sales rise 14%, EBITDA loss narrowsSenzime reported Q3 2026 net sales of TSEK 30,099, up 14% year-over-year, with disposable sensors accounting for 83% of sales. EBITDA loss narrowed to TSEK -8,026 from TSEK -19,395, and the company targets positive cash flow in Q4 2026.Stock TitanSenzime schedules Oct. 29 Q3 report presentationsSenzime will publish its third-quarter 2026 report on October 29, with presentations for investors, analysts, and media. CEO Philip Siberg will present via webcast at 09:00 am CEST, followed by a live Q&A with analyst Gustaf Meyer at 10:00 am CEST.TradingViewInvitation to presentations of Senzime’s third quarter 2026 reportSenzime invites investors, analysts, and media to presentations of its Q3 2026 report on Oct 29, with the report published at 08:00 CEST. CEO Philip Siberg will present via webcast at 09:00 CEST, and analyst Gustaf Meyer will host a live Q&A at 10:00 CEST. Questions can be emailed to Redeye by 10:00 CEST.MarketScreenerSenzime: New studies show improved monitoring and potential cost savingsSenzime presented new research on its TetraGraph system at Anesthesiology 2026, citing a study of 9,938 procedures showing improved monitoring of deep neuromuscular blockade. A health economic model estimates that in 4,000 annual surgeries, 32 postoperative pulmonary complications could be avoided, saving about $1.23 million per year with a 30-day payback.The future of tradingSenzime Study Shows TetraGraph Improves Monitoring During Deep Neuromuscular BlockSenzime presented research at ANESTHESIOLOGY 2026 showing its TetraGraph device improves monitoring during deep neuromuscular block. An economic model estimated $1.23 million in net annual savings from broader quantitative monitoring, with break-even in about 30 days. The study was scheduled for presentation on October 17, 2026.Stock TitanSenzime model estimates $1.23M in annual savingsSenzime presented new data at ANESTHESIOLOGY 2026 on its TetraGraph monitoring system. A hospital economic model estimated $1.23 million in net annual savings from adopting quantitative neuromuscular monitoring, with a break-even period of about 30 days.Stock TitanSenzime plans predictive recovery software launchSenzime announced the upcoming launch of EMGINE Aurora, a software update for its Next-Generation TetraGraph neuromuscular monitor. The update introduces industry-first predictive recovery algorithms and intubation readiness assessment, with features showcased at ANESTHESIOLOGY 2026 in San Diego.